Risk stratification in cardiac disease is the use of biomarker assays and other diagnostic testing of an individual with disease to predict risk of future disease and cardiac events. The results are also utilized in treatment and drug intervention plans.
Studies conducted recently use multiple markers for risk stratification for patients with CHF, ACS, and previous AMIs. Multiple markers (BNP, NT-ProBNP, cardiac troponins, and hs-CRP) may be used in near future to predict short-term and long-term risks of cardiac disease and death. Serial troponin levels are currently measured in those with ischemia to determine the risk of AMI. Troponin levels are used to plan medical and surgical treatments.
